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Background: A diagnosis of psychotic disorder is traditionally considered incompatible 
with borderline personality disorder (BPD), even though patients sometimes fulfill the 
diagnostic criteria for both disorders. How often this happens is barely known, as is the 
influence of comorbid psychotic disorders on the outcome of BPD. Since studies on 
isolated auditory verbal hallucinations in patients with BPD indicate that these perceptual 
symptoms have severe consequences and are associated with suicidal behavior and 
hospitalization, patients with comorbid psychotic disorders are unlikely to fare better.
Objective: To examine the point prevalence of psychotic disorders in patients with BPD, 
their association with the outcome of BPD, and their predictive value for outcome.
Methods: In a cross-sectional design, 84 female outpatients diagnosed with BPD were 
interviewed with the aid of the MINI-International Neuropsychiatric Interview to establish 
the point prevalence of comorbid psychotic and other comorbid disorders. After termi-
nation of their treatment at a specialized outpatient clinic, the type of referral was con-
sidered to be a “good” outcome when they were referred to their general practitioner or 
to basic psychiatric care for noncomplex patients, and a “poor” outcome when referred 
to a specialized psychiatric department or to a psychiatric district team for patients with 
severe psychiatric disorders.
results: Psychotic disorders were present in 38% of the patients with BPD. With a prev-
alence of 20%, psychotic disorder not otherwise specified (NOS) was the most common 
subtype; the least common types were schizophrenia (2%), substance-induced psychotic 
disorder (2%), and brief psychotic disorder (1%). Among six types of comorbid disorders, 
only psychotic disorders were associated with a poor outcome; they were also predictors for 
a poor outcome, along with comorbid mood disorders, eating disorders, and somatoform 
disorders, as well as the severity of BPD, and, counterintuitively, more years of education.
conclusion: Psychotic disorders, notably of the psychotic disorder NOS subtype, are 
common among patients with BPD, and their presence is associated with a poor out-
come. This implies that adequate diagnosis and treatment of both disorders is warranted 
in this subgroup with a dual diagnosis.
Keywords: comorbidity, outcome, predictive value, prevalence, psychotic disorder
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inTrODUcTiOn
Borderline personality disorder (BPD) is conceptualized as a 
combination of affective dysregulation, impulsive/behavioral 
dyscontrol, disturbed interpersonal relatedness, and cognitive-
perceptual symptoms (1–3). Symptoms of the latter include 
suspiciousness, ideas of reference, paranoid ideation, illusions, 
derealization, depersonalization, and hallucination-like symp-
toms. One of the criteria for BPD is that “transient, stress-related 
paranoid ideation may be present” (4). Moreover, psychotic fea-
tures among patients with BPD are “by definition considered as 
mild and transient and hallucination-like in nature.” BPD is often 
accompanied by dissociation, intense episodes of anger, and sui-
cidal ideation and behavior, resulting in functional impairment 
and increased health care utilization (2, 3, 5). Clinical studies 
indicate that BPD can also be accompanied by comorbid disorders 
such as mood and anxiety disorders, substance abuse disorders, 
and eating disorders (6–8). However, few data are available on 
the prevalence of psychotic disorders in patients with BPD. This 
is at least partly due to the fact that classifications such as the 
Diagnostic and Statistical Manual of Mental Disorders [DSM-5 
(4)] and the International Classification of Diseases and Related 
Health Problems [ICD-10 (9)] stipulate that the presence of a 
major psychotic disorder precludes BPD as a diagnosis (10). This 
is unfortunate, as these disorders are characterized by different 
sets of symptoms and, moreover, hallucinations are experienced 
by 26–54% of patients diagnosed with BPD (11–14) and delu-
sions by 17–29% (12, 13, 15). The additional burden caused by 
such psychotic symptoms is often substantial, as is demonstrated, 
for example, by increased levels of distress, more frequent suicide 
plans and attempts, and substantially higher needs for hospitali-
zation in patients with BPD who also suffer from auditory verbal 
hallucinations (16).
Because so little is known about the co-occurrence of psy-
chotic disorders and BPD, it is also unknown to what extent they 
determine the long-term outcome of BPD, which in itself can vary 
substantially, allowing patients to either live meaningful and fairly 
stable lives (whether or not with a partner, children, and a paid 
job) or end up in a secluded nursing ward with highly specialized 
care for the remainder of their lives. The long-term outcome of 
BPD has been investigated in two large-scale prospective cohort 
studies, i.e., the Collaborative Longitudinal Personality Disorders 
Study (17) and the McLean Study of Adult Development (18). In 
these studies, remission rates ranged from 30 to 50% by the second 
year of follow-up, to up to 80% by the tenth year, with the mean 
number of symptoms decreasing steadily over time. Despite these 
encouraging results, some 20% of the patients under study failed 
to recover substantially within 10 years. What distinguishes the 
latter patients from those who did recover is not fully known, 
even though many variables were found to affect the symptomatic 
outcome of BPD, including sociodemographic factors, severity 
of symptoms, personality traits, comorbid posttraumatic stress 
disorder (PTSD), and comorbid substance abuse disorders, 
whereas the co-occurrence of mood disorders, anxiety disorders, 
and eating disorders did not negatively affect outcome (19–21). 
However, since comorbid psychotic disorders, such as schizo-
phrenia, were an exclusion criterium in the above-mentioned 
studies, their influence on the long-term outcome of BPD was 
not assessed.
As insight into the predictive factors for the outcome of BPD 
is urgently needed to allow for optimization of treatment and 
prevention of chronic hospitalization, the present study was 
designed to answer the following questions:
 1. What is the point prevalence of comorbid psychotic disorders 
in patients diagnosed with BPD?
 2. Is the long-term outcome of BPD associated with the presence 
of comorbid psychotic disorders?
 3. Can individual disorders or conditions be identified that 
predict outcome in patients with BPD?
MaTerials anD MeThODs
Participants
Patients with BPD, diagnosed in accordance with the criteria 
issued by the DSM-IV-TR (1) between May 2012 and March 
2015, were recruited at the Department of Personality Disorders 
(an outpatient clinic specialized in the treatment of personality 
disorders) at Parnassia Psychiatric Institute, The Hague. Data col-
lection for this study was part of a treatment protocol described 
in Niemantsverdriet et al. (14). All patients referred to the clinic 
were help seeking. The majority of patients were referred by their 
primary clinician and the remainder by other departments of 
Parnassia Psychiatric Institute. Criteria for inclusion were (i) a 
diagnosis of BPD as established with the aid of the Structural 
Clinical Interview for Axis II Personality Disorders (22), (ii) age 
≥18  years, and (iii) written, informed consent. The study was 
approved by Parnassia’s Institutional Review Board (registration 
number 6237) in accordance with the Declaration of Helsinki.
instruments and Procedure
For this cross-sectional study, the presence of psychotic disorders 
and other comorbid disorders was assessed with the aid of the 
MINI-International Neuropsychiatric Interview [MINI PLUS 
(23)]. Thus, the presence of seven groups of disorders at that 
moment was explored, comprising mood disorders (i.e., depres-
sive disorder, bipolar disorder), anxiety disorders (i.e., panic 
disorder, agoraphobia, social phobia, obsessive-compulsive dis-
order, and general anxiety disorder), substance abuse disorders 
(i.e., alcohol dependence, alcohol abuse, substance (non-alcohol) 
abuse, and substance dependence), PTSD, eating disorders (i.e., 
anorexia nervosa and bulimia nervosa), somatoform disorders 
(i.e., hypochondriasis, body dysmorphic disorder, and pain disor-
der), and psychotic disorders (i.e., schizophrenia, schizoaffective 
disorder, schizophreniform disorder, brief psychotic disorder, 
delusional disorder, psychotic disorder due to a general medical 
condition, substance-induced psychotic disorder, psychotic dis-
order not otherwise specified (NOS), major depressive disorder 
with psychotic features, and bipolar I disorder with psychotic 
features). Thus, we defined psychotic disorders as disorders listed 
in the DSM-5 under the heading of Schizophrenia Spectrum and 
Other Psychotic Disorders, plus three diagnostic categories that 
were included in the MINI PLUS, i.e., psychotic disorders due 
TaBle 1 | Demographic data of patients with borderline personality disorder 
(BPD) with a good and bad long-term outcome.







Age in years (mean, SD) 36 (11.5) 38.5 (12) t = 0.985 0.33
Years of education (mean, SD) 11.1 (2.4) 12.2 (2.4) t = 1.924 0.058
Duration of treatment in  
months (median)
65 70 MWUT 0.38
Number of BPD criteria  
(mean, SD)
6.4 (1.4) 6.7 (1.4) t = 1.073 0.29
Medication
Antipsychotics (%, number) 34% (13) 41% (18) FET 0.50
Antidepressants (%, number) 38% (15) 55% (23) FET 0.19
Mood stabilizers (%, number) 8% (3) 5% (2) FET 0.66
Benzodiazepines (%, number) 24% (9) 31% (13) FET 0.62
Total number of 
psychopharmacological agents 
(mean, SD)
1.1 (1.1) 1.4 (1.1) t = 1.291 0.20
FET, Fisher’s Exact test; MWUT, Mann–Whitney U-test.
TaBle 2 | Frequency of comorbid disorders present in at least one patient with 
borderline personality disorder (total group = 84 patients).
comorbid disorder % (number)
Mood disorder 54 (45)
Anxiety disorder 70 (59)
Posttraumatic stress disorder 41 (34)
Substance abuse disorder 32 (27)
Eating disorder 17 (14)
Somatoform disorder 36 (30)
Psychotic disorders 38 (31)
Mood disorder with psychotic features 6 (5)
Schizophrenia 2 (2)
Schizoaffective disorder 4 (3)
Brief psychotic disorder 1 (1)
Substance-induced psychotic disorder 2 (2)
Psychotic disorder not otherwise specified 20 (17)
Bipolar I disorder with psychotic features 1 (1)
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to a medical condition, mood disorders with psychotic features, 
and substance abuse disorders with psychotic features. Kappa 
coefficient, sensitivity, and specificity were good or very good for 
all diagnoses (i.e., kappa coefficients varied from 0.76 to 0.93), 
with the exception of those for generalized anxiety disorder 
(kappa =  0.36), agoraphobia (sensitivity =  0.59), and bulimia 
nervosa (kappa = 0.53 (23)). Inter-rater and test-retest reliability 
were good.
Interviewers were two psychologists, two residents of psychol-
ogy, and one resident of psychiatry who had been trained in con-
ducting the MINI PLUS. They participated in monthly meetings 
to safeguard the inter-rater reliability during the inclusion phase.
At the outpatient clinic, patients generally remained under 
treatment as long as specialized psychiatric care was expected 
to enable further improvement of their BPD symptoms. When 
this could no longer be reasonably expected, each patient was 
offered four options for further care, comprising (i) referral to 
their general practitioner when psychiatric care was no longer 
necessary, (ii) referral to basic psychiatric care for noncomplex 
patients when they were expected to need ≤800  min of care 
per year, and crisis management was no longer necessary, 
(iii) referral to another specialized psychiatric department when 
treatment of a comorbid disorder was necessary, and (iv) referral 
to a psychiatric district team for patients with severe psychiatric 
disorders when the estimated duration of further treatment was 
≥2 years, problems in psychosocial functioning were present, and 
adjuvant social care was needed. For the present study, outcomes 
(i) and (ii) were defined as “good” and outcomes (iii) and (iv) 
as “poor.” After termination of care at the outpatient clinic, the 
type of follow-up treatment for each individual patient could be 
retrieved from their electronic medical records.
statistical analyses
Data analysis was performed with SPSS version 23 and R ver-
sion 3.3.2. Demographic differences between the two groups 
were analyzed with Chi2 tests, t-tests for independent samples, 
and the Mann–Whitney U-test, as the duration of treatment was 
not normally distributed. Differences in outcome between the 
groups (i.e., good versus poor outcome) in relation to comorbid 
disorders were analyzed with Chi2 tests and odds ratios (OR). 
The Benjamini–Hochberg correction was used to correct for 
multiple testing (24). To search for predictive factors for good 
and poor outcome, a logistic regression analysis was performed. 
As the number of patients was relatively small, we applied elastic 
net regularization (25) using the glmnet package (26) within R 
(27). After exclusion of all cases with missing data, the dataset 
was changed into a dataset with all predictors, and a vector Y 
with the outcome variables. A regression analysis was conducted 
by penalizing regression coefficients to 0, i.e., by decreasing the 
variance of the predictors toward 0. Whenever a variable had 
regression coefficient 0, it was erased from the regression model. 
Two-dimensional cross-validation was used to explore which 
combination of penalization degree and mixture led to the small-
est prediction error (28) applying the one-standard-error rule 
(29). The dependent value was outcome (i.e., good versus poor), 
whereas independent values were age, total years of education, 
total number of BPD criteria, and comorbid disorders.
resUlTs
Descriptives
Included were 84 female patients (and no male patients) with 
BPD; their demographic data are presented in Table  1. The 
treatment of all patients consisted of psychodynamic psycho-
therapy, cognitive-behavioral therapy, schema-focused therapy 
or dialectical behavior therapy, and supporting sessions, either 
individually or in a group. The choice of treatment depended on 
the patient’s capacity to participate within a group setting, their 
introspective ability, and the education of the therapist.
In addition, many of the patients received medication, with 
half of those with a comorbid psychotic disorders using antipsy-
chotics. Treatment duration ranged from 10 to 192 months, with 
89% of the patients being under treatment for ≥24 months.
comorbidity
The point prevalence of comorbid disorders was 17–70%, with 
anxiety disorders being the most prevalent ones and eating disor-
ders the least prevalent ones (Table 2). Psychotic disorders were 
TaBle 4 | Logistic regression analysis for age, total years of education, total 
number of borderline personality disorder (BPD) criteria, comorbid disorders, and 
outcome in patients with BPD.
Factor regression coefficients Odds ratios
Years of education −0.139 0.87
Total number of BPD criteria −0.0769 0.93
Mood disorders −0.0366 0.96
Psychotic disorders −0.108 0.90
Eating disorders −0.577 0.56
Somatoform disorders −0.357 0.70
TaBle 3 | Associations between outcome and comorbid disorders in at least one patient with borderline personality disorder (total group = 84 patients).
Disorder, % (number) good outcome (n = 40) Poor outcome (n = 44) p-Value Odds ratios 95% ci
Mood disorder 48% (19) 59% (26) 0.38 1.6 0.673–3.787
Anxiety disorder 65% (26) 75% (33) 0.35 1.6 0.630–4.145
Posttraumatic stress disorder 35% (14) 46% (20) 0.38 1.5 0.642–3.731
Substance abuse 28% (11) 36% (16) 0.48 1.5 0.596–3.806
Eating disorder 13% (5) 21% (9) 0.39 1.8 0.548–5.913
Somatoform disorder 30% (12) 41% (18) 0.36 1.6 0.654–3.992
Psychotic disorders 25% (10) 50% (21) 0.024 3.0 1.175–7.657
Mood disorder with psychotic features 3% (1) 9% (4) 0.36 3.9 0.417–36.461
Schizophrenia 0 5% (2) 0.50 – –
Schizoaffective disorder 0 7% (3) 0.24 – –
Brief psychotic disorder 3% (1) 0 0.48 – –
Substance-induced psychotic disorder 3% (1) 2% (1) 1.0 0.93 0.056–15.360
Psychotic disorder not otherwise 
specified
18% (7) 23% (10) 0.80 1.2 0.413–3.354
Bipolar I disorder with psychotic features 0 2% (1) 1.0 – –
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present in 38% of the patients. With a point prevalence of 20%, 
psychotic disorder NOS was the most common of these, whereas 
schizophreniform disorder and mood disorders with psychotic 
features were present in 6 and 7% of the patients, respectively. 
Two patients (2%) fulfilled the criteria of schizophrenia and three 
(4%) the criteria of schizoaffective disorder.
Outcome
Of all 84 patients, 40 (48%) were identified as having a good 
outcome and 44 (52%) as having a poor outcome. No statisti-
cal difference was found between these two groups regarding 
demographic factors at baseline, use of medication, or duration of 
treatment. Table 3 shows the associations between all comorbid 
disorders and outcome. The association between psychotic disor-
ders and outcome was significant (OR 3.0; 95% CI 1.175–7.657; 
p = 0.024) but was not significant for all other comorbid disorders.
Predicting Outcome
Regarding the logistic regression analysis, the variables that were 
preserved in the model with optimal penalization were mood 
disorders, psychotic disorders, eating disorders, somatoform 
disorders, more years of education, and total number of BPD 
criteria with the highest OR for eating disorders (Table 4).
DiscUssiOn
This study investigated the point prevalence of psychotic 
disorders in 84 female patients diagnosed with BPD and the 
association of these disorders with outcome. In addition, other 
comorbid disorders, demographic variables, and the severity of 
BPD were explored as predictive factors for outcome. All seven 
groups of comorbid disorders that we assessed were represented 
in our sample, with prevalence rates ranging from 17% for eating 
disorders to 70% for anxiety disorders. Psychotic disorders were 
present in 38% of the patients, with psychotic disorder NOS as 
the most common variant (20%). Schizophrenia was present in 
2% of the patients and schizoaffective disorder in 4%. Despite the 
high prevalence rate of mood disorders among patients with BPD 
(93%), mood symptoms did rarely contribute to a diagnosis of 
psychotic disorders. A significant correlation was found between 
psychotic disorders and (poor) outcome. Psychotic disorders 
also constituted a risk factor for poor outcome, along with mood 
disorders, eating disorders, and somatoform disorders, as well as 
the severity of BPD, and more years of education.
The relatively small numbers of patients diagnosed with schiz-
ophrenia and schizoaffective disorder are in accordance with the 
studies of Thompson et al. (30), Kingdon et al. (12), and Turner 
et al. (31). The remaining diagnostic categories of the group of 
psychotic disorders have hardly been studied in patients with BPD. 
In a prior study of 379 inpatients with BPD, 1.3% had a lifetime 
diagnosis of psychotic disorders, as established with the aid of the 
Structured Clinical Interview for DSM-III-R (7), with no further 
distinction being made for the specific type of psychotic disorder. 
Thompson et al. (30) explored the transition to psychosis within 
24 months in 14 outpatients with an ultra-high risk for psychosis 
and BPD; of whom, 13% developed a schizophrenia spectrum 
disorder (i.e., schizophrenia, schizoaffective disorder, or schizo-
phreniform disorder) and 10% “other psychotic disorders” (i.e., 
brief psychotic disorder, delusional disorder, psychotic disorder 
due to a medical condition, substance-induced psychotic disor-
der, or substance-induced mood disorder with manic features 
and psychotic disorder NOS); no differences in prevalence rates 
between these groups were reported. In a community population 
of 46 patients with non-suicidal self-injury and BPD, the lifetime 
prevalence of psychotic disorders was 4.5% (31). More specifically, 
schizoaffective disorder, substance-induced psychotic disorder, 
and psychotic disorder NOS were present in 2.3, 2.3, and 9.5% of 
the patients, respectively. Finally, in a study by Kingdon et al. (12) 
among 52 inpatients and outpatients with BPD, 37% had BPD 
5Slotema et al. Borderline Personality and Psychotic Disorders
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as well as schizophrenia; the presence of other types of schizo-
phrenia spectrum disorder was not investigated. “Exploring the 
presence of BPD in patients with schizophrenia reveals more or 
less similar prevalence rates, i.e., 2 to 7% (32–35).”
The present study is the first to report on the point prevalence 
of all types of psychotic disorders in conjunction with BPD. 
Although comorbidity of BPD with other disorders (such as 
mood, anxiety, and substance abuse disorders) has been assessed 
before (6), our findings indicate that the clinical impact of comor-
bid psychotic disorders is much more relevant for the outcome 
of BPD. According to our analysis, this group of disorders is 
associated with a poor outcome of BPD and is a predictor for poor 
outcome; however, for this finding, no comparison can be made 
due to lack of prior studies in this specific area. What is known, 
however, is that the presence of auditory verbal hallucinations in 
BPD is associated with a marked increase of suicidal plans and 
attempts and with more frequent hospitalization (16). Moreover, 
it is known that auditory verbal hallucinations in patients with 
BPD often have a relatively long duration (36, 37) and that their 
phenomenological characteristics (as well as the distress they 
evoke) are similar to those in patients diagnosed with schizo-
phrenia (12, 36, 38).
In addition, we found that mood disorders, eating disorders, 
and somatoform disorders are predictors for a poor outcome of 
BPD. This is at odds with prior studies, the majority of which 
reported that comorbid disorders do not predict the outcome of 
BPD at all (19, 39–42). Incidentally, comorbidity with somato-
form disorders was not assessed in these studies.
Thus, our findings for comorbidity with mood and eating 
disorders as predictors for a poor outcome of BPD are at odds 
with the majority of studies, whereas no comparison could be 
made with previous studies on the role of comorbid psychotic 
disorders and somatoform disorders. This is probably because 
previous studies did not include patients with more severe and/
or complex personality disorders. Another reason might be that 
most earlier studies focused on lifetime prevalence rates for 
comorbid disorders, thereby yielding different results.
We do not think that the levels of comorbidity are the result 
of the specialized nature of the clinic, as our clinic is specialized 
in the treatment of personality disorders in general and offers no 
treatment specifically aimed at patients with BPD and psychotic 
features.
Our finding that also the severity of BPD is a predictive factor 
for outcome is in line with others (39, 43). Our final finding, that 
a greater number of years of education is a predictive factor for 
poor outcome, was based on a rather small difference in years 
of education between the two groups, i.e., a mean of 11.1 years 
for the group with a good outcome and 12.2 years for the group 
with a poor outcome. This finding is difficult to explain, as higher 
levels of education are generally viewed as predictors for success 
in life; therefore, replication of this finding is needed.
limitations
The present study has several limitations. First, only female 
patients with BPD were included in the analysis (since only four 
men had enrolled in the study); therefore, our findings cannot 
be generalized to men with BPD. Second, because this study had 
a cross-sectional design, no causal conclusions can be drawn. 
Third, the sample size of 84 patients was relatively small and 
may, therefore, have influenced the power of our study. Fourth, 
because we were unable to collect individual data on the type/
types of psychotherapy that the patients had received, no distinc-
tion could be made regarding the influence of different forms of 
psychotherapy on outcome. Fifth, the MINI Neuropsychiatric 
Interview only assesses the presence of auditory and visual hal-
lucinations and not other hallucinations such as tactile, olfactory, 
or gustatory hallucinations; the prevalence of psychotic disorder 
NOS might be higher if these hallucinations were included. Sixth, 
we did not explore the presence of schizotypal personality disor-
der. Seven percent of the patients with BPD also fulfill the criteria 
for a comorbid schizotypal personality disorder (8), which can 
also be accompanied by psychotic features. The aim of our study, 
however, was to explore the presence of psychotic disorders in a 
sample of patients with BPD as a primary diagnosis. We therefore 
recommend to direct future research at the additional value of 
schizotypal personality disorder within a population of patients 
with BPD and comorbid psychotic features. Finally, we did not 
assess the severity of psychiatric comorbidity, which has been 
associated with greater or lesser symptom improvement (39).
In addition, something that might be construed as a limitation 
(although in our opinion it is not) is the basic premise of our 
study, i.e., that BPD and psychotic disorders can be diagnosed 
simultaneously in individual patients, whereas diagnostic guide-
lines indicate that, in such cases, a diagnosis of psychotic disorders 
should prevail over BPD. The reason why we do not concur with 
this approach is that clinical practice indicates that patients can 
fulfill the diagnostic criteria of both disorders, that both disorders 
tend to show only few overlapping symptoms, and that both dis-
orders require their own type of psychiatric treatment. That said, 
we agree that careful diagnosis is of ultimate importance in such 
cases and that, sometimes, patients may need to be rediagnosed 
when either of the two disorders is substantially more prominent 
than the other, or when patients initially diagnosed with BPD go 
on to develop a major psychotic disorder. Thus, in the present 
sample, the two patients diagnosed with “comorbid” schizophre-
nia and the three with schizoaffective disorder, might have to be 
relabeled at some point in time as suffering from schizophrenia or 
a related disorder, rather than from BPD. Nevertheless, this does 
not contradict the finding that, during our study, they did fulfill 
the diagnostic criteria of both disorders, and that the overwhelm-
ing majority of patients in our study did not fulfill the criteria for 
a major psychotic disorder.
implications for clinical Practice and 
Future research
Our findings imply that more attention should be paid to the 
presence of psychotic disorders in patients diagnosed with BPD 
and, if present, efforts should be directed at offering these patients 
specialized treatment for both disorders since both require differ-
ent treatments, and outcome depends substantially on the pres-
ence or absence of a comorbid psychotic disorders. That said, the 
inevitable question of what type of treatment should be offered is 
not an easy one to answer, since little is known about the treatment 
6Slotema et al. Borderline Personality and Psychotic Disorders
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of psychosis in patients with BPD. In clinical practice, only a 
minority of BPD patients receive treatment specifically aimed at 
their psychotic symptoms. This is reflected in our own patient 
sample, in which only half of those with a comorbid psychotic 
disorders were treated with antipsychotics. As an alternative, 
inspiration might be derived from the field of psychotic disorders, 
where many evidence-based interventions have been developed, 
including antipsychotics, cognitive-behavioral therapy, and 
transcranial magnetic stimulation (44, 45); of these three, only 
the effects of antipsychotics have been studied in patients with 
BPD and cognitive-perceptual symptoms, such as suspiciousness, 
referential thinking, paranoid ideation, derealization, deperson-
alization, illusions, and related perceptual symptoms (46). Three 
meta-analyses have shown small to moderate effect sizes of this 
approach (46–48). The reason why effect sizes were not larger 
might be due to the tendency of clinicians to prescribe relatively 
low doses of antipsychotics for patients with BPD. In the studies 
mentioned, the effects of antipsychotics on the severity of specific 
psychotic symptoms were not assessed. Taken cumulatively, these 
results indicate that there is a need for further studies on the 
efficacy of antipsychotics and other interventions for psychotic 
symptoms and disorders in patients with BPD, preferentially of 
a design that makes it possible to take the severity of symptoms 
into account. Regarding psychotherapeutic treatment for BPD 
with comorbid depression, a number of studies has shown 
mixed results (49–51), whereas a combined treatment for BPD 
and eating disorders yielded positive results (52, 53). So far, it 
is unknown whether other comorbid disorders improve during 
treatment of BPD, with or without adjuvant strategies specifically 
directed at them. Therefore, future studies should focus on these 
types of treatment in BPD with comorbid disorders.
cOnclUsiOn
In our sample, psychotic disorders, especially of the subtype of 
psychotic disorder NOS, affected 38% of the patients diagnosed 
with BPD. The presence of such comorbid disorders is associated 
with a poor outcome and even serves as a predictive factor for 
poor outcome, along with current mood, eating disorders, and 
somatoform disorders, the severity of BPD, and more years of 
education. These findings imply that more attention should be 
paid to the treatment of psychotic disorders and other comorbid 
disorders in patients with BPD.
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